BCLI

Brainstorm Cell Therapeutics Inc.

0.36 USD
-0.01 (-1.53%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Brainstorm Cell Therapeutics Inc. stock is down -7.44% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 65% of the previous 19 February’s closed higher than January.

About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. It is developing NurOwn, which has completed Phase III clinical trial for the. treatment of amyotrophic lateral sclerosis; and Phase II clinical trial. for. progressive multiple sclerosis and alzheimer's disease. The company was formerly known as Golden Hand Resources Inc.